The impact of cancer survivors’ extra risk of noncancer mortality on net survival estimation - Summary - MDSpire

The impact of cancer survivors’ extra risk of noncancer mortality on net survival estimation

  • By

  • Laura Botta

  • Riccardo Capocaccia

  • Alice Bernasconi

  • Silvia Rossi

  • Jaume Galceran

  • Luigino Dal Maso

  • Come Lepage

  • Florence Molinié

  • Anne-Marie Bouvier

  • Rafael Marcos-Gragera

  • Claudia Vener

  • Marcela Guevara

  • Deirdre Murray

  • Rosalia Ragusa

  • Gemma Gatta

  • Valerie Jooste

  • the EUROCARE-6 WG

  • M Hackl

  • E Van Eycken

  • N Van Damme

  • Z Valerianova

  • M Sekerija

  • V Scoutellas

  • A Demetriou

  • L Dušek

  • D Krejici

  • H Storm

  • M Mägi

  • K Innos

  • J Pitkäniemi

  • M Velten

  • X Troussard

  • A M Bouvier

  • V Jooste

  • A V Guizard

  • G Launoy

  • S Dabakuyo Yonli

  • M Maynadié

  • A S Woronoff

  • J B Nousbaum

  • G Coureau

  • A Monnereau

  • I Baldi

  • K Hammas

  • B Tretarre

  • M Colonna

  • S Plouvier

  • T D'Almeida

  • F Molinié

  • A Cowppli-Bony

  • S Bara

  • A Debreuve

  • G Defossez

  • B Lapôtre-Ledoux

  • P Grosclaude

  • L Daubisse-Marliac

  • S Luttmann

  • A Eberle

  • R Stabenow

  • A Nennecke

  • J Kieschke

  • S Zeissig

  • B Holleczek

  • A Katalinic

  • H Birgisson

  • D Murray

  • P M Walsh

  • G Mazzoleni

  • F Vittadello

  • F Cuccaro

  • R Galasso

  • G Sampietro

  • S Rosso

  • C Gasparotti

  • G Maifredi

  • M Ferrante

  • R Ragusa

  • A Sutera Sardo

  • M L Gambino

  • M Lanzoni

  • P Ballotari

  • E Giacomazzi

  • S Ferretti

  • A Caldarella

  • G Manneschi

  • G Gatta

  • M Sant

  • P Baili

  • F Berrino

  • L Botta

  • A Trama

  • R Lillini

  • A Bernasconi

  • S Bonfarnuzzo

  • C Vener

  • F Didonè

  • P Lasalvia

  • L Buratti

  • G Tagliabue

  • D Serraino

  • L Dal Maso

  • R Capocaccia

  • R De Angelis

  • E Demuru

  • F Cerza

  • F Di Mari

  • C Di Benedetto

  • S Rossi

  • M Santaquilani

  • S Venanzi

  • M Tallon

  • L Boni

  • S Iacovacci

  • V Gennaro

  • A G Russo

  • F Gervasi

  • G Spagnoli

  • L Cavalieri d'Oro

  • M Fusco

  • M F Vitale

  • P Pinna

  • W Mazzucco

  • M Michiara

  • G Chiranda

  • G Cascone

  • M C Giurdanella

  • L Mangone

  • F Falcini

  • R Cavallo

  • D Piras

  • A Madeddu

  • F Bella

  • A C Fanetti

  • S Minerba

  • G Candela

  • T Scuderi

  • R V Rizzello

  • F Stracci

  • M Zorzi

  • S Guzzinati

  • A Brustolin

  • S Pildava

  • I Vincerzevskiene

  • M Azzopardi

  • T B Johannesen

  • J Didkowska

  • U Wojciechowska

  • M Bielska-Lasota

  • A Pais

  • M J Bento

  • C Alves-Rodrigues

  • A Lourenço

  • A Mayer

  • C Safaei Diba

  • V Zadnik

  • T Zagar

  • C Sánchez-Contador Escudero

  • P Franch Sureda

  • A Lopez de Munain

  • M De-La-Cruz

  • M D Rojas

  • A Aleman

  • A Vizcaino

  • R Marcos-Gragera

  • A Sanvisens

  • M J Sanchez

  • M D Chirlaque Lopez

  • A Sanchez-Gil

  • M Guevara

  • E Ardanaz

  • J Galceran

  • M Carulla

  • Y Bergeron

  • E Rapiti

  • R Schaffar

  • S Mohsen Mousavi

  • P Went

  • S Mohsen Mousavi

  • M Blum

  • A Bordoni

  • O Visser

  • S Siesling

  • S Stevens

  • J Broggio

  • D Bennett

  • A Gavin

  • D Morrison

  • D W Huws

  • August 19, 2025

  • 0 min

Share

Objective:

To evaluate the impact of increased noncancer mortality risk on net survival (NS) estimates in cancer patients compared to the general population, highlighting the differences in mortality risks.

Key Findings:
  • Differences between RS and true NS values are larger for older patients, longer time since diagnosis, and higher NS.
  • For head and neck cancer, differences ranged from 4% for young females at 5 years to 32% for older patients.
  • Colorectal cancer showed differences of less than 7% across demographics, while breast cancer differences were under 5% except for older patients after 5 years.
  • If RR > 1, RS underestimates NS, indicating a significant bias.
Interpretation:

The findings highlight the biases in using RS as a proxy for NS due to the increased risk of noncancer mortality in cancer patients, emphasizing the need for accurate NS estimation to inform clinical decisions.

Limitations:
  • The study relies on theoretical models and may not capture all real-world complexities, potentially limiting the applicability of the findings.
  • Data limitations from EUROCARE-6 may affect the generalizability of findings, particularly in diverse populations.
Conclusion:

Accurate interpretation of NS is crucial for understanding cancer survival and planning post-treatment care, as RS may not reflect true cancer-specific survival due to varying noncancer mortality risks, necessitating improved estimation methods.

Original Source(s)

The impact of cancer survivors’ extra risk of noncancer mortality on net survival estimation

  • by Laura Botta, Riccardo Capocaccia, Alice Bernasconi, Silvia Rossi, Jaume Galceran, Luigino Dal Maso, Come Lepage, Florence Molinié, Anne-Marie Bouvier, Rafael Marcos-Gragera, Claudia Vener, Marcela Guevara, Deirdre Murray, Rosalia Ragusa, Gemma Gatta, Valerie Jooste, the EUROCARE-6 WG, M Hackl, E Van Eycken, N Van Damme, Z Valerianova, M Sekerija, V Scoutellas, A Demetriou, L Dušek, D Krejici, H Storm, M Mägi, K Innos, J Pitkäniemi, M Velten, X Troussard, A M Bouvier, V Jooste, A V Guizard, G Launoy, S Dabakuyo Yonli, M Maynadié, A S Woronoff, J B Nousbaum, G Coureau, A Monnereau, I Baldi, K Hammas, B Tretarre, M Colonna, S Plouvier, T D'Almeida, F Molinié, A Cowppli-Bony, S Bara, A Debreuve, G Defossez, B Lapôtre-Ledoux, P Grosclaude, L Daubisse-Marliac, S Luttmann, A Eberle, R Stabenow, A Nennecke, J Kieschke, S Zeissig, B Holleczek, A Katalinic, H Birgisson, D Murray, P M Walsh, G Mazzoleni, F Vittadello, F Cuccaro, R Galasso, G Sampietro, S Rosso, C Gasparotti, G Maifredi, M Ferrante, R Ragusa, A Sutera Sardo, M L Gambino, M Lanzoni, P Ballotari, E Giacomazzi, S Ferretti, A Caldarella, G Manneschi, G Gatta, M Sant, P Baili, F Berrino, L Botta, A Trama, R Lillini, A Bernasconi, S Bonfarnuzzo, C Vener, F Didonè, P Lasalvia, L Buratti, G Tagliabue, D Serraino, L Dal Maso, R Capocaccia, R De Angelis, E Demuru, F Cerza, F Di Mari, C Di Benedetto, S Rossi, M Santaquilani, S Venanzi, M Tallon, L Boni, S Iacovacci, V Gennaro, A G Russo, F Gervasi, G Spagnoli, L Cavalieri d'Oro, M Fusco, M F Vitale, P Pinna, W Mazzucco, M Michiara, G Chiranda, G Cascone, M C Giurdanella, L Mangone, F Falcini, R Cavallo, D Piras, A Madeddu, F Bella, A C Fanetti, S Minerba, G Candela, T Scuderi, R V Rizzello, F Stracci, M Zorzi, S Guzzinati, A Brustolin, S Pildava, I Vincerzevskiene, M Azzopardi, T B Johannesen, J Didkowska, U Wojciechowska, M Bielska-Lasota, A Pais, M J Bento, C Alves-Rodrigues, A Lourenço, A Mayer, C Safaei Diba, V Zadnik, T Zagar, C Sánchez-Contador Escudero, P Franch Sureda, A Lopez de Munain, M De-La-Cruz, M D Rojas, A Aleman, A Vizcaino, R Marcos-Gragera, A Sanvisens, M J Sanchez, M D Chirlaque Lopez, A Sanchez-Gil, M Guevara, E Ardanaz, J Galceran, M Carulla, Y Bergeron, E Rapiti, R Schaffar, S Mohsen Mousavi, P Went, S Mohsen Mousavi, M Blum, A Bordoni, O Visser, S Siesling, S Stevens, J Broggio, D Bennett, A Gavin, D Morrison, D W Huws

  • August 19, 2025

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • by

  • May 7, 2026

  • 4 min